Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma's Phase 3 Clinical Trial Results

CHICAGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint but showed several encouraging results that suggest real potential for patients living with this rare disease. While the trial (conducted in 268 patients in the U.S., Europe, Japan, and Brazil) did not achieve the primary goal of reducing oral corticosteroid use ...